| General Information | |
|---|---|
| ZINC ID | ZINC000028345229 |
| Molecular Weight (Da) | 451 |
| SMILES | O=C(NN1CCCCC1)c1nc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)o1 |
| Molecular Formula | C21Cl3N3O2 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 113.466 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| LogP | 6.08 |
| Activity (Ki) in nM | 467.735 |
| Polar Surface Area (PSA) | 58.37 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.82809585 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.24 |
| Ilogp | 3.94 |
| Xlogp3 | 6.23 |
| Wlogp | 5.72 |
| Mlogp | 4.2 |
| Silicos-it log p | 5.46 |
| Consensus log p | 5.11 |
| Esol log s | -6.66 |
| Esol solubility (mg/ml) | 0.0000979 |
| Esol solubility (mol/l) | 0.00000021 |
| Esol class | Poorly sol |
| Ali log s | -7.24 |
| Ali solubility (mg/ml) | 0.0000258 |
| Ali solubility (mol/l) | 5.73E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.72 |
| Silicos-it solubility (mg/ml) | 0.00000085 |
| Silicos-it solubility (mol/l) | 1.91E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.63 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.64 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.52 |
| Logd | 4.941 |
| Logp | 5.612 |
| F (20%) | 0.001 |
| F (30%) | 0.009 |
| Mdck | - |
| Ppb | 100.77% |
| Vdss | 2.776 |
| Fu | 0.65% |
| Cyp1a2-inh | 0.64 |
| Cyp1a2-sub | 0.527 |
| Cyp2c19-inh | 0.85 |
| Cyp2c19-sub | 0.097 |
| Cl | 6.187 |
| T12 | 0.018 |
| H-ht | 0.946 |
| Dili | 0.98 |
| Roa | 0.294 |
| Fdamdd | 0.158 |
| Skinsen | 0.051 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.731 |
| Bcf | 2.442 |
| Igc50 | 4.87 |
| Lc50 | 6.411 |
| Lc50dm | 5.363 |
| Nr-ar | 0.008 |
| Nr-ar-lbd | 0.052 |
| Nr-ahr | 0.949 |
| Nr-aromatase | 0.946 |
| Nr-er | 0.787 |
| Nr-er-lbd | 0.007 |
| Nr-ppar-gamma | 0.928 |
| Sr-are | 0.94 |
| Sr-atad5 | 0.805 |
| Sr-hse | 0.574 |
| Sr-mmp | 0.92 |
| Sr-p53 | 0.951 |
| Vol | 410.022 |
| Dense | 1.095 |
| Flex | 0.208 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 2 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.522 |
| Synth | 2.573 |
| Fsp3 | 0.238 |
| Mce-18 | 52.462 |
| Natural product-likeness | -0.973 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |